Literature DB >> 12430886

The simplification of the SCT procedures in developing countries has resulted in cost-lowering and availability to more patients.

David Gómez-Almaguer1.   

Abstract

In order to simplify and cutting down expenses of the bone marrow transplantation procedures we have made some efforts, trying to provide the best transplantation technique for the individual patient with scarce resources. In relation with the source of stem cells, we have found very attractive the use of peripheral blood stem cells (PBSC) instead of bone marrow cells. This procedure can produce substantially more rapid engraftment than observed with bone marrow. The rapid hematopoietic reconstitution in the recipient of PBSC lower expenses stemming from the use of antibiotics, blood bank products and days at the hospital. In Mexico, a country with a large number of cases of severe aplastic anemia we decided to use PBSC to transplant 10 patients with this disease, in order to take advantage of the large number of stem cells that this procedure can provide. We had excellent results in these patients, avoiding the high cost of the conventional transplantation and the use of ATG. In relation to autologous transplantation we have made efforts to perform autografts without the use of freezing devices, keeping the stem cells in liquid form using a conventional blood bank refrigerator for up to 96 hr. This modifications have resulted in diminishing costs and increasing the availability of the procedure to a large number of patients. Finally in Mexico we have had experience with non-myeloablative transplants, and obtained reasonably good results, with a median cost of 18,000 USD per allogeneic transplantation procedure. In some cases this is the only affordable therapeutic option. In developing countries where very few patients can afford the cost of conventional bone marrow transplants, any reasonable effort in the direction of simplification must be welcome.

Entities:  

Mesh:

Year:  2002        PMID: 12430886     DOI: 10.1007/bf03165288

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  14 in total

1.  Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.

Authors:  G J Ruiz-Argüelles; D Gómez-Almaguer; A Ruiz-Argüelles; O González-Llano; O G Cantú; J C Jaime-Pérez
Journal:  Am J Hematol       Date:  2001-04       Impact factor: 10.047

2.  Filgrastim-mobilized peripheral-blood stem cells can be stored at 4 degrees and used in autografts to rescue high-dose chemotherapy.

Authors:  G J Ruiz-Argüelles; A Ruiz-Argüelles; B Pérez-Romano; A Marín-López; A Larregina-Díez; M G Apreza-Molina
Journal:  Am J Hematol       Date:  1995-02       Impact factor: 10.047

3.  Simplification of the blood stem cell transplantation (BSCT) procedure: large volume apheresis and uncontrolled rate cryopreservation at -80 degrees C.

Authors:  W W Feremans; G Bastin; F L Moine; C Ravoet; J P Delville; O Pradier; G Wallef; E Dupont; P Capel; M Lambermont
Journal:  Eur J Haematol       Date:  1996-05       Impact factor: 2.997

4.  The evolution of clinical peripheral blood stem cell transplantation.

Authors:  M Körbling; T M Fliedner
Journal:  Bone Marrow Transplant       Date:  1996-05       Impact factor: 5.483

5.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

Authors:  S Giralt; E Estey; M Albitar; K van Besien; G Rondón; P Anderlini; S O'Brien; I Khouri; J Gajewski; R Mehra; D Claxton; B Andersson; M Beran; D Przepiorka; C Koller; S Kornblau; M Kørbling; M Keating; H Kantarjian; R Champlin
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

6.  Involvement of donor T-cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection.

Authors:  P J Martin; Y Akatsuka; M Hahne; G Sale
Journal:  Blood       Date:  1998-09-15       Impact factor: 22.113

7.  Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases.

Authors:  D Gómez-Almaguer; G J Ruiz-Argüelles; A Ruiz-Argüelles; O González-Llano; O E Cantú; N E Hernández
Journal:  Bone Marrow Transplant       Date:  2000-01       Impact factor: 5.483

8.  High-dose peripheral blood stem cell transplant for multitransfused severe aplastic anaemia patients without antithymocyte globulin in the conditioning regimen.

Authors:  J Herrera-Garza; J Jaime-Pérez; J Montemayor; R Ibarra-Peart; D Gómez-Almaguer
Journal:  Bone Marrow Transplant       Date:  1999-10       Impact factor: 5.483

9.  Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation.

Authors:  W I Bensinger; R Clift; P Martin; F R Appelbaum; T Demirer; T Gooley; K Lilleby; S Rowley; J Sanders; R Storb; C D Buckner
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

10.  Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia.

Authors:  R Storb; R Etzioni; C Anasetti; F R Appelbaum; C D Buckner; W Bensinger; E Bryant; R Clift; H J Deeg; K Doney
Journal:  Blood       Date:  1994-08-01       Impact factor: 22.113

View more
  3 in total

1.  Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in northeast Mexico.

Authors:  José Carlos Jaime-Pérez; Alberto Carlos Heredia-Salazar; Olga G Cantú-Rodríguez; Homero Gutiérrez-Aguirre; César Daniel Villarreal-Villarreal; Consuelo Mancías-Guerra; José Luís Herrera-Garza; David Gómez-Almaguer
Journal:  Oncologist       Date:  2015-03-06

2.  Survival of Mexican children with acute myeloid leukaemia who received early intensification chemotherapy and an autologous transplant.

Authors:  Elva Jiménez-Hernández; María Teresa Dueñas-González; José Arellano-Galindo; María Elena Medrano-Ortíz-De-Zárate; Vilma Carolina Bekker-Méndez; Adolfina Berges-García; Karina Solís-Labastida; Berenice Sánchez-Jara; Héctor Manuel Tiznado-García; Ethel Zulie Jaimes-Reyes; Xochiketzalli García-Jiménez; Laura Espinoza-Hernández; Nora Nancy Núñez-Villegas; Sergio Franco-Ornelas; Ruy Xavier Pérez-Casillas; Octavio Martínez Villegas; Teresa Marin Palomares; Juan Manuel Mejía-Aranguré
Journal:  Biomed Res Int       Date:  2015-03-02       Impact factor: 3.411

Review 3.  Outpatient allogeneic hematopoietic stem-cell transplantation: a review.

Authors:  David Gómez-Almaguer; Andrés Gómez-De León; Perla R Colunga-Pedraza; Olga G Cantú-Rodríguez; César Homero Gutierrez-Aguirre; Guillermo Ruíz-Arguelles
Journal:  Ther Adv Hematol       Date:  2022-02-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.